Development and evaluation of drugs: From laboratory through licensure to market, second edition

Development and Evaluation of Drugs: From Laboratory through Licensure to Market, Second Edition

Volumn , Issue , 2003, Pages 1-243

  Lee, Chi Jen ^a   Lee, Lucia H ^a   Lu, Cheng Hsiung ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b CHUNGTAI INST HLTH SCI TECHNOL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85056071241     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Book

References (257)

1. Chen, K.K. and Schmidt, C.F., Ephedrine and related substances, Medicine (Baltimore), 9, 1, 1930.
2. Burgen, A.S.V., The road to rational drug design, in Innovative Approaches in Drug Research, Harms, A.F. (Ed.), Elsevier Publishing Company, 1986, 1.
3. Sarel, S., Mechoulam, R., and Agranat, I. (Eds.), Rational drug design, in Trends in Medicinal Chemistry ’90, Blackwell Scientific, Oxford, 1992, 55.
4. Marshall, G.R., Computer-aided drug design, Annu. Rev. Pharmacol. Toxicol., 27, 193, 1987.
5. Vedani, A. and Meyer, E.F. Jr., Structure-activity relationships of sulfonamide drugs and human carbonic anhydrase C: modeling of inhibitor molecules into the receptor site of the enzyme with an interactive computer graphics display, J. Pharm. Sci., 73, 352, 1984.
6. Smith, G.H., Hangauer, D.G., Andose, J.D., Bush, B.L., Fluder, E.M., et al., Intermolecular modeling methods in drug design: modeling the mechanism of peptide cleavage by thermolysin, Drug Inf. J., 18, 167, 1984.
7. Hendry, L.B., Bransome, E.D. Jr., Lehner, A.F., Muldoon, T.G., Hutson, M.S., and Mahest, V.B., The stereochemical complementarity of DNA and reproductive steroid hormones correlates with biological activity, J. Steroid Biochem. Mol. Biol., 24(4):843, 1986.
8. Ilza, V., Huang Ti Nei, Ching Su Wen, The Yellow Emperor’s Classic of Internal Medicine, Williams & Wilkins, Baltimore, 1949, 253.
9. Needham, J., The Tao chia (Taoists) and Taoism, in Science and Civilization in China. Vol. 2, History of Scientific Thought, Cambridge University Press, Cambridge, 1956.
10. Lee, C.J., Bacterial capsular polysaccharides — biochemistry, immunity and vaccine, Mol. Immunol., 24:1005, 1987.
11. Dubos, R. and Dubos, J., Hygeia and Asclepius, in Mirage of Health, Harper & Brothers, New York, 1959, 109.
12. Pharmaceutical Manufacturers Association, Biotechnology medicines in development, Gene. Eng. News, 27, 1992.
13. Gordon, S.L., Overview of the commercial prospects for biotechnology products in health care, in Copsey, D.N. and Delnatte, S.Y.J. (Eds.), Genetically Engineered Human Therapeutic Drugs, Macmillan, New York, 1988, 137.
14. Chiou, G.C.Y., Systemic delivery of polypeptide drugs through ocular route, Annu. Rev. Pharmacol. Toxicol., 31:457, 1991.
15. Pharmaceutical Research and Manufacturers of America, Biotechnology Medicines in Development, Washington, D.C., 1996.
16. Lee Jr., K.B., Burrill, G.S., Biotech 96, The Industry Annual Report, 1995, Ernst and Young LLP.
17. Sindelar, R.D., Additional biotechnology-related techniques, in Pharmaceutical Biotechnology, Crommelin, D.J.A. and Sindelar, R.D. (Eds.), Harwood Academic Publishers, Amsterdam, 1997, 123–166.
18. Shapiro, B., Merck and Co., The impact of biotechnology on drug discovery, 9th International Congress of Immunology, San Francisco, 1995.
19. Struck, M.M., Biopharmaceutical R & D success rates and development times, Bio/Technology, 12, 674–677, 1994.
20. Yuan, R.T. and Dibner, M.D., Japanese Biotechnology: A Comprehensive Study of Government Policy, R & D, and Industry, Macmillan, London, 1990.
21. Collins, F.S. and Jegalian, K.G., Deciphering the code of life, Sci. Am., 281(6): 86–91, 1999.
22. Collins, F.S., Genome project, N. Engl. J. Med., 341:28–37, 1999.
23. Green, E., The Human Genome Project and its impact on the study of human disease, in Metabolic and Molecular Bases of Inherited Disease, 8th ed., Scriver, C.R. (Ed.), McGraw-Hill, New York, 2000.
24. Pennisi, E., Are sequencers ready to annotate the human genome? Science, 287:2183, 2000.
25. Searls, D.B., Using bioinformatics in gene and drug discovery, Drug Discovery Today, 5:135–143, 2000.
26. Howard, K., The bioinformatics gold rush, Sci. Am., 283(1):58–63, 2000.
27. Abbott, A., A post-genomic challenge: learning to read patterns of protein synthesis, Nature, 402:715–720, 1999.
28. Ezzell, C., Beyond the human genome, Sci. Am., 283(1):64–69, 2000.
29. U.S. Government, Elimination of the establishment license application for specified biotechnology and specified synthetic biological products. Federal Register, 61, 94, Washington, D.C., U.S. Government Printing Office; 1996:24227–24233.
30. Walsh, G., The drug development process, in Biopharmaceuticals: Biochemistry and Biotechnology, John Wiley & Sons, New York, 1998, 37–74.
31. Bugg, C.E., Carson, W.M., and Montgomery, J.A., Drugs by design, Sci. Am., 269(6):92–98, 1993.
32. Biddle, J.A., Technology transfer: what you always wanted to know but were afraid to ask, in Vaccines — From Concept to Clinic, Paoletti, L.C. and McInnes, P.M. (Eds.), CRC Press, Boca Raton, FL, 1999, 127–174.
33. The Pharmaceutical Affairs Bureau, Information on the guidelines of toxicity studies required for applications for approval to manufacture (import) drugs. I. GLP Regulation and Toxicity Tests Guidelines, Pharmaceutical Affairs Publication Co., Tokyo, 1984, 359.
34. Code of Federal Regulations, Nonclinical laboratory studies, good laboratory practice (GLP) regulations, Title 21 part 58, FDA, Rockville, MD, 1991, 233–246.
35. Lee, C.J., Ishimura, K., Nakajima, T., and Huang, J. T., New drug development and good laboratory practice (GLP) in the United States, Lab. Animal Sci. & Technol., 2:95–105, 1990 (Japanese).
36. James, G., FDA’s good laboratory practice regulations at home and abroad, presented at Center for Biologics, FDA, Bethesda, MD, October 4, 1988, p. 1–17.
37. Hussein, G. and Bleidt, B., Pharmacokinetics: interactions of new drugs and the human body, in Clinical Research in Pharmaceutical Development, Bleidt, B. and Montagne, M. (Eds.), Marcel Dekker, New York, 1997, 109–124.
38. Braeckman, R., Pharmacokinetics and pharmacodynamics of peptide and protein drugs, in Pharmaceutical Biotechnology, Crommelin, D.J.A. and Sindelar, R.D. (Eds.), Harwood Academic Publishers, Australia, 1997, 101–120.
39. Baumann, G., Shaw, M.A., and Buchanan, T.A., In vivo kinetics of a covalent growth hormone-binding protein complex, Metabolism, 38:330–333, 1988.
40. Mohler, M.A., Cook, J.E., and Baumann, G., Binding proteins of protein therapeutics, in Protein Pharmacokinetics and Metabolism, Ferraiolo, B.L., Hohler, M.A., and Gloff, C.A. (Eds.), Plenum Press, New York, 1992, 35–71.
41. Chiou, W.L., Ma, C., Chung, S.M. et al., Similarity in the linear and non-linear oral absorption of drugs between human and rat, Int. J. Clin. Pharm. Ther., 38:532–539, 2000.
42. Chiou, W.L. and Barve, A., Linear correlation of the fraction of oral dose absorbed of 64 drugs between human and rats, Pharm. Res., 15:1792–1795, 1998.
43. Chiou, W.L., Jeong, H.Y., Chung, S.M., and Wu, T.C., Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans, Pharm. Res., 17:135–140, 2000.
44. Walter, R.J., Bulk drug substances and purity: a regulatory viewpoint, Pharm. Technol., 10, 35, 1984.
45. Yang, W.H., Statistical treatment of stability data, Drug Develop. Ind. Pharm., 7:63–77, 1981.
46. Center for Drugs and Biologics, Draft guideline for stability studies for human drugs and biologics, 1984. Food and Drug Administration, Rockville, MD, 1984.
47. Grimm, W., Stability testing in industry for world wide marketing, Drug Develop. Ind. Pharm., 12:1259–1292, 1986.
48. Schirmer, R.E., Modern Methods of Pharmaceutical Analysis, 2nd ed., CRC Press, Boca Raton, FL, 1991.
49. Adamovids, J.A. (Ed.), Chromatographic Analysis of Pharmaceuticals, Marcel Dekker, New York, 1990, 83.
50. Kline, B.J. and Soine, W.H., Gas chromatography: theory, instrumentation, and pharmaceutical applications, in Pharmaceutical Analysis, Modern Methods, Munson, J.W. (Ed.), Marcel Dekker, New York. Part A 1981, Part B 1984, 1.
51. Main, K.B. and Medwick, T., Analysis of medicinals, in Remington’s Pharmaceutical Sciences, 18th ed., Gennaro, A.R. (Ed.), Mark Publishing, Easton, PA, 1990, 435.
52. Flieger, K., Testing in real people, in New Drug Development in the United States, Rockville, MD, Food and Drug Administration, 1988.
53. Code of Federal Regulations, Investigational new drug application, Title 21, Part 312, Food and Drug Administration, Rockville, MD, 1991, 61.
54. Kessler, D.A., The regulation of investigational drugs, N. Engl. J. Med., 320, 281, 1989.
55. Zivin, J.A., Understanding clinical trials, Sci. Am., 282(4):69–75, 2000.
56. Lo, B., Wolfe, L.E., and Berkeley, A., Conflict-of-interest policies for investigators in clinical trials, N. Engl. J. Med., 343(22):1616–1620, 2000.
57. Martin, J.B. and Kasper D.L., In whose best interest? Breaching the academic-industrial wall, N. Engl. J. Med., 343(22):1646–1649, 2000.
58. Cohn, J.P., The beginnings: laboratory and animal studies, in New Drug Development in the United States, Food and Drug Administration, Rockville, MD, 1988, 8–11.
59. www.fda.gov/oc/pdufa/PDUFAIIIgoals.html.
60. Code of Federal Regulations, Applications for FDA market approval for a new drug or an antibiotic drug, Title 21, Part 314, Food and Drug Administration, Rockville, MD, 1991, 95–138.
61. Valle, M.A.D., HVAC systems for biopharmaceutical manufacturing plants, Bio-Pharmacology, April, 26, 1989.
62. Lee, J.Y., Environmental requirements for clean rooms, BioPharmacology, 2, 42, 1989.
63. Bjurstrom, E.E. and Coleman, D., Water systems for biotechnology facilities, BioPharmacology, September, 50, 1987.
64. U.S. Pharmacopoeia, 23rd ed. Water for pharmaceutical purposes, p. 1984; Sterile water for injection, p. 1636, United States Pharmacopoeial Convention, Rockville, MD, 1995.
65. World Health Organization, Internal drug monitoring: the role of the hospital — a WHO report, Drug Intell. Clin. Pharm., 4:101–110, 1970.
66. Code of Federal Regulations, Postmarketing reporting of adverse drug experiences, Title 21, Part 314, Food and Drug Administration, Rockville, MD, 1991, 108–114.
67. Talley, R.B. and Laventurier, M.F., Drug induced illness, JAMA, 229:1043, 1974.
68. Stewart, R.B., Adverse drug reactions, in Remington’s Pharmaceutical Sciences, 18th ed., Gennaro, A.R. (Ed.), Mark Printing Company, Easton, PA, 1990, 1330–1343.
69. Boyer, K.M., Theeravuthichal, J., Vogel, L.C., Orlina, A., and Gotoff, S.P., Antibody response to Group B streptococcus type III and AB blood group antigens, J. Pediat., 98:374–378, 1981.
70. Siber, G.R., Ambrosino, D.M., and Gorgone, G.C., Blood group A-like substances in pneumococcal vaccine, Ann. Int. Med., 96:580–586, 1982.
71. Luzzio, J., Demonstration of blood group substance A bound to Pasteurella pestis, Proc. Soc. Exp. Biol. Med., 131:853–858, 1969.
72. Mollison, P.L., Antibodies of the ABO system, in Blood Transfusion in Clinical Medicine, 5th ed., Blackwell Scientific Publications, London, 1972, 246–248.
73. Springer, G.F., Blood group A active substances in embrionated chicken eggs and their relation to egg-grown virus, Science, 138:687–688, 1962.
74. Springer, G.F., Influenza virus vaccine and blood group A-like substances. Letter to the editor, Transfusion, 3:233–236, 1963.
75. Springer, G.F., Shuster, R., and Tritel, H., Influenza vaccine and isoimmunization, Am. J. Clin. Path., 42:589–598, 1964.
76. Oravec, L.S., Lee, C.J., Ann Hoppe, P., and Santos, C.V., Detection of blood group A-like substance in bacterial and viral vaccines by countercurrent immunoelectrophoresis using Helix pomatia lectin, J. Biol Stand., 12:159–166, 1984.
77. Faich, G.A., Dreis, M., and Tomita, D., National adverse drug reaction surveillance, 1986, Arch. Intern. Med., 148:785–787, 1988.
78. Rogers, A.S., Israel, E., Smith, C.R., Levine, D., McBean, A.M., Valente, C., and Faich, G., Physician knowledge, attitudes, and behavior related to reporting adverse drug events, Arch. Intern. Med., 148:1595–1600, 1988.
79. Tanaka, K., Morita, Y., Kawabe, E. et al., Drug use investigation (DUI) and prescription-event monitoring in Japan (J-PEM), Pharmacoepidemiol. Drug Saf., 10(7): 653–658, 2001.
80. Chen, S.T., Re-inventing drug regulation in Asian pacific: the Taiwan experience and a vision for the region, in Professional Frontiers in the 21st Century, Lee, C.J. (Ed.), Chinese-American Professionals Association, Washington, D.C., 2002, 3.1–3.5.
81. Chu, M.L., Chern, H.D., Chen, J.J., and Chen, S., Evaluation of drugs and biologics in Taiwan, in Professional Frontiers in the 21st Century, Lee, C.J. (Ed.), Chinese-American Professionals Association, Washington, D.C., 2002, 3.6–3.15.
82. Chen, K.C., Building the infrastructure of clinical trials in Taiwan, in Professional Frontiers in the 21st Century, Lee, C.J. (Ed.), Chinese-American Professionals Association, Washington, D.C., 2002, 3.16–3.23.
83. Hopps, H.E., Meyers, B.C., and Parkman, P.D., Regulation and testing of vaccines, in Vaccines, Plotkin, S.A. and Mortimer, E.A. (Eds.), Saunders Company, Philadelphia, 1988, 576.
84. Adams, W.G. Deaver, K.A., and Cochi, S.L., Decline of childhood Haemophilus influenzae type b (Hib) disease in the Hib vaccine era, JAMA, 269:221–226, 1993.
85. Lee, C.J., Banks, S.D., and Li, J.P., Virulence, immunity, and vaccine related to Streptococcus pneumoniae, Crit. Rev. Microbiol., 18(2), 89, 1991.
86. World Health Organization, Proposed requirements for pneumococcal polysaccharide vaccine, WHO/BS/79.1251, Rev. 1, Geneva, Switzerland, 1980, 1.
87. Abeygunawardana, C., Williams, T.C., Summer, J.S. et al., Development and validation of an NMR-based identity assay for bacterial polysaccharides, Anal. Biochem., 279:226–240, 2000.
88. Lee, L.H., Lee, C.J., and Frasch, C.E., Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control tests, Crit. Rev. Microbiol., 28(1):27–41, 2002.
89. Lee, C.J., Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry, J. Biologicals, 29:1045–56, 2002.
90. Romero-Steiner, S., Libutti, D., Pais, L.B. et al., Standardization of an opsono-phagocytic assay for the measurement of functional antibody activity against Streptococcus pneumoniae using differentiated HL-60 cells, Clin. Diag. Lab. Immunol., 4:415–422, 1997.
91. Pilikaytis, B.D., Goldblatt, D., Frasch, C.E. et al., An analytical model applied to a multicenter pneumococcal enzyme-linked immunosorbent assay study, J. Clin. Microbiol., 38:2043–2050, 2000.
92. Lee, L.H., Frasch, C.E., Falk, L.A. et al., Correlates of immunity for pneumococcal conjugate vaccines, Vaccine, 2003 (in press).
93. Code of Federal Regulations, Bioequivalence requirements, Title 21, Part 320, Food and Drug Administration, Rockville, MD, 1991, 151–157.
94. Haffner, M.E., Orphan products: origins, progress, and prospect, Annu. Rev. Pharmacol. Toxicol., 31, 603, 1991.
95. Cato, A.E., Stang, P., and Sutton, R.O., Orphan drug development: David and Goliath, in Clinical Drug Trials and Tribulations, Cato, A.E. (Ed.), Marcel Dekker, New York, 1988, 227.
96. Orphan drugs, in Drug Evaluations Annual 1991, American Medical Association, Milwaukee, WI, 1991, 67.
97. Gibalde, M., Prolonged-release medication, Perspect. Clin. Pharmacol., 2:17–53, 1984.
98. Goldstein, A., Aronow, L., and Kalman, S.M., Principles of Drug Action: The Basis of Pharmacology, 2nd ed., John Wiley & Sons, New York, 1974.
99. Jacquz, E., Hall, S.D., and Branch, R.A., Genetically determined polymorphisms in drug oxidation, Hepatology, 6:1020–1032, 1986.
100. Anders, M.W., Metabolism of drugs by the kidney, Kidney Int., 18:636–647, 1980.
101. Cockcroft, D.W. and Gault M.H., Prediction of creatinine clearance from serum creatinine, Nephron, 16:31–41, 1976.
102. Rowland, M. and Tozer, T.N., Clinical Pharmacokinetics: Concepts and Applications, 2nd ed., Lea & Febiger, Philadelphia, 1989.
103. Matzke, G.R. and St Peter, W.L., Clinical pharmacokinetics 1990, Clin. Pharmacokinet., 18 (1):1–19, 1990.
104. Chen, M.L., Regulatory overview of bioavailability and bioequivalence, in Professional Frontiers in the 21st Century, Lee, C.J. (Ed.), Chinese-American Professionals Association, Washington, D.C., 2002, 3.43–3.47.
105. Malinowski, H.J., Bioavailability and bioequivalence testing, in Remington: The Science and Practice of Pharmacy, 20th ed., Gennaro, A.R. (Ed.), Lippincott Williams & Wilkins, Baltimore, MD, 2000, 995–1004.
106. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products – General Considerations, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, MD, October 2000.
107. Chen, M.L., Lesko, L.J., and Williams, R.L., Measure of exposure versus measures of rate and extent of absorption, Clin. Pharmacokinet., 40(8):565–572, 2001.
108. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Office of Training and Communications Management, Drug Information Branch, HFD-210, Rockville, MD, August 2000.
109. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlation, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, MD, September 1997.
110. Schuirmann, D.J., A comparison of the two one-sided tests procedure and the power approach for assessing the bioequivalence of average bioavailability, J. Pharmacokinet. Biopharm., 15:657–680, 1987.
111. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, MD, January 2001.
112. Chen, M.L., Patnaik, R., Hauck, W.W. et al., An individual bioequivalence criterion: regulatory considerations, Stat. Med., 19:2821–2842, 2000.
113. Hauck, W.W., Hyslop, T., Chen, M.L. et al., Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues, Pharm. Res., 17:375–380, 2000.
114. Welling, P.G., Interactions affecting drug absorption, Clin. Pharmacokinet., 9:404–434, 1984.
115. Moore, R.B., Crane, C.A., and Frantz, Jr., I.D., Effect of cholestyramine on the fecal excretion of intravenously administered cholesterol-4–14C and its degradation productions in a hypercholesterolemic patient, J. Clin. Invest., 47:1664–1671, 1968.
116. Neuvonen, P.J. and Turakka, H., Inhibitory effect of various iron salts on the absorption of tetracycline in man, Eur. J. Clin. Pharm., 7:357–360, 1974.
117. Alvares, A.P., Pantuck, E.J., Anderson, K.E., Kappas, A., and Conney, A.H., Regulation of drug metabolism in man by environmental factors, Drug Metab. Rev., 9(2):185–205, 1979.
118. Welling, P.G., Interactions affecting drug absorption, Clin. Pharmacokinet., 9:404–434, 1984.
119. Campbell, T.C. and Hayes, J.R., Role of nutrition in the drug-metabolizing enzyme system, Pharmacol. Rev., 26:171–197, 1974.
120. Vestal, R.E. and Wood, A.J.J., Influence of age and smoking on drug kinetics in man: studies using model compounds, Clin. Pharmacokinet., 5:309–319, 1980.
121. Dollery, C.T., Fraser, H.S., Mucklow, J. C., and Bulpitt, C.J., Contribution of environmental factors to variability in human drug metabolism, Drug Metab. Rev., 9:207–220, 2979.
122. Lieber, C.S., Interaction of ethanol with drugs and vitamin therapy, Ration. Drug Ther., 19:1–7, 1985.
123. Iber, F.L., Drug metabolism in heavy consumers of ethyl alcohol, Clin. Pharmacol. Ther., 22:735–742, 1977.
124. Vesell, E.S., Pharmacogenetics: multiple interactions between genes and environment as determinants of drug response, Am. J. Med., 66:183–187, 1979.
125. Vessell, E.S., Genetic host factors: determinants of drug response, N. Engl. J. Med., 313:261–262, 1985.
126. Bennett, W.M., Arnoff, G.R., Morrison, G.M., Golper, T.A., Pulliam, J., Wolson, M., and Singer, I., Drug prescribing in renal failure: dosing guidelines for adults, Am. J. Kidney Dis., 3:155–193, 1983.
127. Reidenberg, M.M. and Drayer, D.E., Drug therapy in renal failure, Annu. Rev. Pharmacol. Toxicol., 20:45–54, 1980.
128. Bircher, J., Altered drug metabolism in liver disease: therapeutic implications, in Recent Advances in Hepatology, Thomas, H.C. and Macsween, R.N.M. (Eds.), Churchill-Livingston, London, 1983, 101–113.
129. Williams, R.L. and Benet, L.Z., Drug pharmacokinetics in cardiac and hepatic disease, Annu. Rev. Pharmacol. Toxicol., 20:389–413, 1980.
130. Morselli, P.L., Franco-Morselli, R., and Bossi, L., Clinical pharmacokinetics in newborns and infants: age-related differences and therapeutic implications, Clin. Pharmacokinet., 5:485–527, 1980.
131. Green, T.P. and Mirkin, B.L., Clinical pharmacokinetics: pediatric considerations, in Pharmacokinetic Basis for Drug Treatment, Benet, L.Z., Massoud, N., and Gambertoglio, J.G. (Eds.), Raven Press, New York, 1984, 269–282.
132. American Association of Retired Persons, Prescription Drugs: A Survey of Consumer Uses, Attitudes, and Behavior, AARP, Washington, D.C., 1984.
133. Massoud, N., Pharmacokinetic considerations in geriatric patients, in Pharmacokinetic Basis for Drug Treatment, Benet, L.Z., Massoud, N., and Gambertoglio, J.G. (Eds.), Raven Press, New York, 1984, 283–310.
134. Greenblatt, D.J., Sellers, E.M., and Shader, R.I., Drug disposition in old age, N. Engl. J. Med., 306:1081–1088, 1982.
135. McInnes, G.T. and Brodie, M.J., Drug interactions that matter — a critical reappraisal, Drugs, 36:83–110, 1988.
136. Ross, E.M., Pharmacodynamics: mechanisms of drug action and the relationship between drug concentration and effect, in The Pharmacological Basis of Therapeutics, Gilman, A.A., Goodman, L.S., Rall, T.W., and Murad, F. (Eds.), 7th ed., Macmillan, New York, 1985, 35–48.
137. Keirns, J.J. and Farina, P.R., Drug action and receptor theory, in Modern Drug Research — Path to Better and Safer Drugs, Martin, Y.C., Kutter, E., and Austel, V. (Eds.), Marcel Dekker, New York, 1989, 1–34.
138. 2-receptor agonists and antagonist, in Burger’s Medicinal Chemistry, Wolf, M.D. (Ed.), John Wiley & Sons, New York, 3:487–552, 1981.
139. Chung, F.Z., Wang, C.D., Potter, P.C., Venter, J.C., and Fraser, C.M., Site directed mutagenesis and continuous expression of human beta-adrenergic receptors: identification of a conserved aspartate residue involved in agonist binding and receptor activation, J. Biol. Chem., 263:4052–4055, 1988.
140. Fraser, C.M., Chung, F.Z., Wang, C.D., and Venter, J.C., Site directed mutagenesis of human beta-adrenergic receptors substitution of aspartic acid-130 by asparagine produces a receptor with high-affinity agonist binding that is uncoupled from adenylate cyclase, Proc. Nat. Acad. Sci. USA, 85:5478–5482, 1988.
141. Holmgren, J., Actions of cholera toxin and the prevention and treatment of cholera, Nature, 292:413–417, 1981.
142. Vaughan, M., Choleragen, adenylate cyclase, and ADP-ribosylation, Harvey Lectures, 77:43–62, 1982.
143. Gawler, D., Milligan, G., Spiegel, A.M., Unson, C.G., and Houslay, M.D., Abolition of the expression of inhibitor guanine nucleotide regulatory protein Gi activity in diabetes, Nature, 327:229–232, 1987.
144. Kenakin, T., Drug and receptors — an overview of the current state of knowledge, Drugs, 40(5):666–687, 1990.
145. Miller, D.D., Structure-activity relationship and drug design, in Remington’s Pharmaceutical Sciences, 18th ed., Gennaro, A.R. (Ed.), Mark Printing Company, Easton, PA, 1990, 422–432.
146. Stewart, R.B., Adverse drug reactions, in Remington’s Pharmaceutical Sciences, 18th ed., Gennaro, A.R. (Ed.), Mark Printing Company, Easton, PA, 1990, 1330–1343.
147. Faich, G.A., Knapp, D., Dreis, M., and Turner, W., National adverse drug reaction surveillance: 1985, JAMA, 257:2068–2070, 1986.
148. D’Arcy, P.F. and Griffin, J.P. (Eds.), Iatrogenic Diseases, 3rd ed., Oxford University Press, Oxford, 1986.
149. Jick, H., Miettinen, O.S., Shapiro, S., Lewis, G.P., Suskind, V., and Slone, D., Comprehensive drug surveillance, JAMA, 213:1455–1460, 1970.
150. Kramer, M.S., Leventhal, J. M., Hutchinson, T.A., and Feinstein, A.R., An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions on use, JAMA, 242:623–632, 1979.
151. Hutchinson, T.A., Leventhal, J. M, Kramer, M.S., Karch, F.E., Lipman, A.G., and Feinstein, A.R., An algorithm for the operational assessment of adverse drug reactions. II. Demonstration of reproducibility and validity, JAMA, 242:633–638, 1979.
152. Davies, D.M., Textbook of Adverse Drug Reactions, Oxford University Press, Oxford, 1985.
153. Moya, F. and Thorndike, V., Passage of drugs across the placenta, Am. J. Obstet. Gynecol., 84:1778–1798, 1962.
154. Timiras, P.S., Course of pregnancy, early embryonic stages, and differentiation, in Developmental Physiology and Aging, Timiras, P.S. (Ed.), Macmillan, New York, 1972, 61–78.
155. Iams, J.D., and Rayburn, W.F., Drug effects on fetus, in Drug Therapy in Obstetrics and Gynecology, Rayburn, W.F. and Zuspan, F.P. (Eds.), Appleton-Century-Crofts, Norwalk, CT, 1982, 9–17.
156. Davies, D.M., Disorders of the fetus and infant, in Textbook of Adverse Drug Reactions, Davies, D.M. (Ed.), Oxford University Press, Oxford, 1985, 78–127.
157. Millstein, L.G. FDA’s pregnancy categories, N. Engl. J. Med., 303:706, 1980.
158. Committee on Drugs, American Academy of Pediatrics, Transfer of drugs and other chemicals into human milk, Pediatrics, 84:924–936, 1989.
159. Beeley, L., Adverse effects of drugs in later pregnancy, Clin. Obstet. Gynecol., 13:197–214, 1986.
160. Briggs, G.G., Drugs in Pregnancy and Lactation, 3rd ed., Williams & Wilkins, Baltimore, MD, 1990.
161. Burger, A., Drug design, in Drug Development, Hamner, C.E. (Ed.), CRC Press, Boca Raton, FL, 1982, 53.
162. Martin, Y.C., Kutter, E., and Austel, V. (Eds.), Modern Drug Research: Paths to Better and Safer Drugs, Marcel Dekker, New York, 1989.
163. Clarks, C.R. and Moos, W.H. (Eds.), Drug design, in Drug Discovery Techniques, John Wiley & Sons, New York, 1990, 1.
164. Newall, C., Injectable cephalosporin antibiotics: cephalothin to ceftazidime, in Medicinal Chemistry — The Role of Organic Chemistry in Drug Research, Roberts, S. and Price, B. (Eds.), Academic Press, London, 1985, 209.
165. Daniels, T.C. and Jorgensen, E.C., Physicochemical properties in relation to biological action, in Wilcon and Gisvold’s Textbook of Organic Medicinal Chemistry and Pharmaceutical Chemistry, 8th ed., Doerge, R.F. (Ed.), Lippincott, Philadelphia, 1982, 5.
166. Nogrady, T., Receptor-effector theories, in Medicinal Chemistry, A Biochemical Approach, 2nd ed., Oxford University Press, New York, 1988, 58.
167. Miller, D.D., Structure-activity relationship and drug design, in Remington’s Pharmaceutical Sciences, 18th ed., Gennaro, A.R. (Ed.), Mark Printing Company, Easton, PA, 1990, 422.
168. Blankley, C.J., Introduction: a review of QSAR methodology, in Quantitative Structure–Activity Relationship of Drugs, Topliss, J.G. (Ed.), Academic Press, New York, 1983, 1.
169. Martin, Y.C., Other mathematical methods of use in quantitative structure–activity studies, in Quantitative Drug Design, Marcel Dekker, New York, 1978, 233.
170. Lien, E.J., QSAR in medicinal chemistry: an overview, Chinese Pharm. J., 42, 93, 1990.
171. Kollman, P., Molecular modeling, Annu. Rev. Phys. Chem., 38, 303, 1987.
172. Rogers, E.F., The antimetabolite concept in drug design, Annu. Rev. Med. Chem., 11, 233, 1976.
173. Burger, A., Drug design, in Drug Development, 2nd ed., Hamner, C.E. (Ed.), CRC Press, Boca Raton, FL, 1990, 39.
174. Pharmaceutical Manufacturers Association, Biotechnology medicines in development, Gene. Engin. News, 12 (January), 27, 1992.
175. Dibner, M.D., The impact of biotechnology on the pharmaceutical industry, in Drug Development, 2nd ed., Hamner, C.E. (Ed.), CRC Press, Boca Raton, FL, 1990, 241.
176. Hilleman, M.R., Present and future control of human hepatitis B by vaccination, in Modern Biotechnology and Health: Perspectives for the Year 2000, Patarroyo, M.E., Zaabriskie, J.B., and Pizano-Salazar, D. (Eds.), Academic Press, Orlando, 1987, 199.
177. Sykrybalo, W., Emerging trends in biotechnology: perspective from the pharmaceutical industry, Pharm. Res., 4, 361, 1987.
178. Marderosian, A.H., Biotechnology and drugs, in Remington’s Pharmaceutical Sciences, 18th ed., Gennaro, A.R. (Ed.), Mark Printing Company, Easton, PA, 1990, 1416.
179. Lee, C.J., Ishimura, K., Nakajima, T., and Huang, J.T., New drug development and good laboratory practice (GLP) in the United States, Lab. Animal Sci. Technol., 2, 95, 1990.
180. Kesterson, J.W., Preclinical drug discovery and development, in Clinical Drug Trials and Tribulations, Cato, A.E. (Ed.), Marcel Dekker, New York, 1988, 17.
181. Sheiner, L.B. and Benet, L.Z., Premarketing observational studies of population pharmacokinetics and new drugs, Clin. Pharmacol. Ther., 38, 481, 1985.
182. Cato, A.E., The challenge of the clinical development of drugs, in Clinical Drug Trials and Tribulations, Cato, A.E. (Ed.), Marcel Dekker, New York, 1988, 1.
183. Cloutier, G. and Cato, A.E., Overall clinical drug development planning, in Clinical Drug Trials and Tribulations, Cato, A.E. (Ed.), Marcel Dekker, New York, 1988, 51.
184. Ackerman, S.K., Biological products in phase I and phase II clinical trials, in Clinical Drug Trials and Tribulations, Cato, A.E. (Ed.), Marcel Dekker, New York, 1988, 173.
185. Grass IV, G.M. and Robinson, J.R., Sustained-and controlled-release drug delivery systems, in Modern Pharmaceutics, Bander, G.S. and Rhodes, C.T. (Eds.), Marcel Dekker, New York, 1990, 635.
186. Tomlinson, E., Site-specific drug delivery using particulate systems, in Modern Pharmaceutics, Bander, G.S. and Rhodes, C.T. (Eds.), Marcel Dekker, New York, 1990, 673.
187. Gregoriadis, G. and Neerunjun, E.D., Homing of liposomes to target cells, Biochem. Biophys. Res. Commun., 65, 537, 1975.
188. Juliano, R.L. and Stamp, D., Lectin-mediated attachment of glycoprotein-bearing liposomes to cells, Nature, 261, 235, 1976.
189. Gregoriadis, G., Meehan, A., and Mah, M.M., Interaction of antibody-bearing small unilamellar liposomes with target free antigen in vitro and in vivo, Biochem. J., 200, 203, 1981.
190. Weissman, G., Bloomgarden, D., Kaplan, R. et al., A general method for the introduction of enzymes, by means of immunoglobulin-coated liposomes, into lysosomes of deficient cells, Proc. Natl. Acad. Sci. U.S.A., 72, 88, 1975.
191. Code of Federal Regulations, Current good manufacturing practice for finished pharmaceuticals, Title 21, Part 211, FDA, Rockville, MD, 1990, 76.
192. Lee, C.J., Immunomodulating polysaccharides in plant medicine, in Managing Biotechnology in Drug Development, CRC Press, Boca Raton, FL, 1996, 120–126.
193. Mitscher, L.A., Pillai, S., and Shankel, D.M., Some transpacific thoughts on the regulatory need for standardization of herbal medical products, J. Food Drug Anal., 8 (4):229–234, 2000.
194. Center for Drug Evaluation and Research, Guidance for industry botanical drug products, CDER, Food and Drug Administration, Rockville, MD, 2001, 1–48. http://www.fda.gov/cder/guidance
195. Otsuka, Y. Pharmacotherapy in oriental medicine, in Recent Advances in the Pharmacology of Kampo (Japanese Herbal) Medicines, Hosoya, E. and Yamamura, Y. (Eds.), Excerpta Medica, Tokyo, 1988, xvii-xxi.
196. Lee, C.J. and Lu, C.S., Studies on immunomodulating herbal polysaccharides, in Professional Frontiers in the 21st Century, Chinese–American Professionals Association of Metropolitan Washington, D.C., 2002, 3.32–3.42.
197. Public Health Service, Healthy people: the surgeon general’s report on health promotion and disease prevention, Health and Human Services, U.S. Government Printing Office, Washington, D.C., 1982.
198. Edelman, C.L. and Mandle, C.L., Health defined: promotion and specific protection, in Health Promotion throughout the Lifespan, 2nd ed., The C.V. Mosby Company, St. Louis, MO, 1990, 3–15.
199. Snader, T.C., Long-term care facilities, in Remington’s Pharmaceutical Sciences, 18th ed., Gennaro, A.R. (Ed.), Mark Printing Company, Easton, PA, 1990, 1758–1772.
200. Lee, C.J., Lee, L.H., and Koizumi, K., Polysaccharide vaccines for prevention of encapsulated bacterial infections: part I, Infect. Med., 19(3):127–133, 2002.
201. Lee, C.J., Lee, L.H., and Koizumi, K., Polysaccharide vaccines for prevention of encapsulated bacterial infections: part II, Infect. Med., 19(4):179–182, 2002.
202. Lee, L.H., Lee, C.J., and Frasch, C.E., Development and evaluation of pneumococcal conjugate vaccines: clinical trials and control test, Crit. Rev. Microbiol., 28(1):27–41, 2002.
203. Gurunathan, S., Klinman, D.M., and Seder, R.A., DNA vaccines: immunology, application, and optimization, Annu. Rev. Immunol., 18:927–974, 2000.
204. Weiner D.B. and Kennedy, R.C., Genetic vaccines, Sci. Am., July 1999, 50–57.
205. Tuteja, R., DNA vaccines: a ray of hope, Crit. Rev. Biochem. Mol. Biol., 34(1):1–24, 1999.
206. Seder, R.A. and Gurunathan, S., DNA vaccines — designer vaccines for the 21st century, N. Engl. J. Med., 341;277–278, 1999.
207. Martin, T., Parker, S.E., Hedstrom, R. et al., Plasmic DNA malaria vaccine: the potential for genomic integration after intramuscular injection, Hum. Gene Ther., 10:759–768, 1999.
208. Mor, G., Singla, M., Steinberg, A.D. et al., Do DNA vaccines induce autoimmune disease? Hum. Gene Ther., 8:293–300, 1997.
209. Mor, G., Yamshchikov, G., Sedegah, M. et. al., Induction of neonatal tolerance by plasmid DNA vaccination of mice, J. Clin. Invest., 98:2700–2705, 1996.
210. Ichino, M., Mor, G., Conover, J. et al., Factors associated with the development 1of neonatal tolerance after the administration of a plasmid DNA vaccine, J. Immunol., 162:3814–3818, 1999.
211. Langridge, W.H. Edible vaccines, Sci. Am., September 2000, 66–71
212. Arntzen, C.J. and Mason, H.S., Oral vaccine production in the edible tissues of transgenic plants, in New Generation Vaccines, 2nd ed., revised and expanded, Levine, M.M., Woodrow, G.C., Kaper, J.B., and Cobon, G.S. (Eds.), Marcel Dekker, New York, 1977, 263–277.
213. Mason, H.S., Tacket, C.O., Richter, L.J. et al., Subunit vaccines produced and delivered in transgenic plants as “edible vaccines,” Rev. Immunol., 149:71–74, 1998.
214. Haq, T.A., Mason, H.S., Clements, J.D., and Arntzen, C.J., Production of an orally immunogenic bacterial protein in transgenic plants: proof of concept of edible vaccine, Science, 268:714–716, 1995.
215. Mason, H.S., Ball, J., Shi, J.J. et al., Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity, Proc. Natl. Acad. Sci. USA, 93:5335–5340, 1996.
216. Eisenberg, D.M., Davis, R.B., Ettner, S.L. et al., Trends in alternative medicine uses in the United States, 1990–1997. Results of a follow-up national survey, JAMA, 20:1569–1575, 1998.
217. Bannerman, R., Burton, J., and Chen, W.C. (Eds.), Traditional Medicine and Health Care Coverage, World Health Organization, Geneva, Switzerland, 1983.
218. Lee, K.H., Wang, H.K., Itokawa, H. et al., Current perspectives on Chinese medicines and dietary supplements in China, Japan, and the United States, J. Food Drug Anal., 8(4):219–228, 2000.
219. Hosoya, E., Scientific reevaluation of Kampo prescriptions using modern technology, in Recent Advances in the Pharmacology of Kampo Medicines, Hosoya, E. and Yamamura, Y. (Eds.), Excerpta Medica, Tokyo, 1988, 17–29.
220. Kobashi, K., Glycosides are natural prodrugs — evidence using germ-free and gnotobiotic rats associated with a human intestinal bacterium, J. Trad. Med., 15:1–13, 1998.
221. Yamada, H., The role of bioactive polysaccharides in Kampo medicines, in Pharmacological Research on Traditional Herbal Medicines, Watanabe, H. and Shibuya, T. (Eds.), Harwood Academic Publishers, Amsterdam, The Netherlands, 2000, 179–198.
222. Lee, C.J., Immunomodulating polysaccharides in plant medicine, in Managing Biotechnology in Drug Development, Lee, C.J. (Ed.), CRC Press, Boca Raton, FL, 1966, 120–123.
223. Lee, C.J., Koizumi, K., Koizumi, M., and Aburada, M., Immunomodulating effects of polysaccharides isolated from herbal products, J. Trad. Med., 16:175–182, 1999.
224. Wetzel, M.S., Kaptchuk, T.J., Haramati, A. et al., Complementary and alternative medical therapies: implication for medical education, Ann. Intern. Med., 138:191–196, 2003.
225. Eisenberg, D.M., Davis, R.B., Ettner, S.L. et al., Trends in alternative medicine use in the United States, 1990–1997, JAMA, 280 (18):1569–1609, 1998.
226. Jonas, W.B., Alternative medicine — learning from the past, examine the present, advancing to the future, JAMA, 280(18):1616–1618, 1998.
227. Fontanarosa, P.B. and Lundberg, G.D., Alternative medicine meets science, JAMA, 280(18):1618–1619, 1998.
228. Brenner, M.K., Human somatic gene therapy: progress and problems, J. Inter. Med., 237:229–239, 1995.
229. Blaese, M., Gene therapy for cancer, Sci. Am., June p. 111–120, 1997.
230. Watanabe, S., Kimira, M., and Sobue, T., Diet and cancer: epidemiological approaches, in Food Factors for Cancer Prevention, Ohigashi, H., Osawa, T., Terao, J. et al. (Eds.), Springer-Verlag, Tokyo, 1997, 3–8.
231. Greenwald, P., Diet and cancer prevention in the United States, in Food Factors for Cancer Prevention, Ohigashi, H., Osawa, T., Terao, J. et al. (Eds.), Springer-Verlag, Tokyo, 1997, 30–35.
232. Nishibe, S., Bioactive phenolic compounds for cancer prevention from herbal medicines, in Food Factors for Cancer Prevention, Ohigashi, H., Osawa, T., Terao, J. et al. (Eds.), Springer-Verlag, Tokyo, 1997, 276–279.
233. Waldo, D.R., Levit, K.R., and Lazenby, H., National health expenditures, 1985, Health Care Financing Rev., 8:1, 1986.
234. Pearson, C., National health expenditures 1986–2000, Health Care Financing Rev., 8(4):1, 1987.
235. DiMasi, J.A., Bryant, N.R., and Lasagna, L., New drug development in the United States from 1963 to 1990, Clin. Pharmacol. Therap., 50:471–486, 1991.
236. Koplan, J.P., Schoenbaum, S.C., Weinstein, M.C., and Fraser, D.W., Pertussis vaccine — an analysis of benefits, risks and costs, N. Engl. J. Med., 301(17):906–911, 1979.
237. Hinman, A.R. and Koplan, J.P., Pertussis and pertussis vaccine — reanalysis of benefits, risks and costs, JAMA, 251(23):3109–3113, 1984.
238. Weisbrod, B., Cost and benefits of medical research: a case study of poliomyelitis, J. Polit. Econ., 79:527–544, 1971.
239. Office of Technology Assessment, Update of federal activities regarding the use of pneumococcal vaccine, U.S. Government Printing Office, Washington, D.C., May, 1984.
240. Sisk, J.E. and Riegelman, R.K., Cost effectiveness of vaccination against pneumococcal pneumonia: an update, Ann. Int. Med., 104:79–86, 1986.
241. Kirkman-Liff, B. and Dandoy, S., Cost of hepatitis B prevention in hospital employees: post-exposure prophylaxis, Infect. Cont., 5(8):385–389, 1984.
242. Center for Biologics Evaluation and Research, Human resource expenditures for licensure of MSD’s Haemophilus b conjugate vaccine, Food and Drug Administration, Rockville, MD, December 1991.
243. White, C.C., Koplan, J.P., and Orenstein, W.A., Benefits, risks and costs of immunization for measles, mumps and rubella, Am. J. Publ. Health, 75:739–744, 1985.
244. Center for Disease Control, Diphtheria-tetanus-pertussis vaccine shortage — United States, Mort. Morb. Wk. Rep., 33, 695, 1984.
245. Public law 96–660, The National Childhood Vaccine Injury Act of 1986, 1986.
246. World Bank, World Development Report, Oxford University Press (for the World Bank), New York, 1992.
247. Velander W.H., Lubon, H., and Drohan, W., Transgenic livestock as drug factories, Sci. Am., p. 70–74, January 1997.
248. Campbell, K.H.S., McWhir, J., Ritchie, W.A., and Milmut, I., Sheep cloned by nuclear transfer from a cultured cell line, Nature, 385:810–813, 1997.
249. Schnieke, E. et al., Human factor IX transgenic sheep produced by transfer of nuclei from transfected fetal fibroblasts, Science, 278:2130–2133, 1997.
250. Gibbs, J.B., Mechanism-based target identification and drug discovery in cancer research, Science, 287:1969–1973, 2000.
251. Margolis, S. and Carter, H.B. In the Johns Hopkins White Paper on Prostate Disorders, Johns Hopkins Medical Institutions, Baltimore, 1997.
252. Garnick, M.B. and Fair, W.R., Prostate cancer, Sci. Am., p. 75–83, December 1998.
253. George-Hyslop, P.H., Piecing together Alzheimer’s, Sci. Am., p. 76–83, December 2000.
254. CDC. Update: Investigation of bioterrorism-related anthrax — Connecticut, 2001, Morb. Mort. Wk. Rep., 50:1077–1079, 2001.
255. Inglesby, T.V., Henderson, D.A., Bartlett, J.G. et al., Anthrax as a biological weapon — medical and public health management, JAMA, 281:1735–1745, 1999.
256. HHS Fact Sheet. HHS initiative prepares for possible bioterrorism threat. http://www.hhs.gov/news/press/2000pres/20000518.html, May 18, 2000.
257. Cohen, J., and Marshall, E., Vaccines for biodefense: a system in distress, Science, 294:498–501, 2001.